Pharmacotherapy in Pediatric Hematopoietic Cell Transplantation

Handbook of Experimental Pharmacology
Rick Admiraal, Jaap Jan Boelens

Abstract

Hematopoietic cell transplantation (HCT) is a curative treatment option for both malignant and nonmalignant diseases. Success of the procedure mainly depends on disease control and treatment-related complications. Pharmacotherapy plays a major role in HCT and significantly impacts the outcomes. Main drug use within HCT includes conditioning, GvHD prophylaxis, and prevention/treatment of infections.Increasing evidence suggests individualized dosing in (pediatric) HCT may improve outcome. Dose individualization may result in a better predictable drug treatment in terms of safety and efficacy, including timely immune reconstitution after HCT and optimal tumor or disease control, which may result in improved survival chances.

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Expert Opinion on Pharmacotherapy
Andrew R Rezvani, Rainer Storb
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Coco de KoningStefan Nierkens
Hematology/oncology Clinics of North America
T G GrossF O Smith
© 2021 Meta ULC. All rights reserved